Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study
Alan F. List(TE Laboratories (Ireland)), Frederick R. Appelbaum(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), James H. Doroshow(National Cancer Institute), Cheryl L. Willman(Mayo Clinic), Marilyn L. Slovak(City Of Hope National Medical Center), David R. Head(University of Southern California), Kenneth J. Kopecky(City Of Hope National Medical Center), Robert T. Dorr(SWOG Cancer Research Network), Harry E. Hynes, Diane L. Persons(SWOG Cancer Research Network), Muhammad Shurafa(SWOG Cancer Research Network), Chatchada Karanes(Erasmus MC Cancer Institute)
Cited by 419
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k